| DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update |
Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif. , May 13, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update. |
prnewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript |
DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Co-Founder, Chief Executive Officer, President, Director Norman Sussman - Chief Medical Officer WeiQi Lin - Executive Vice President, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer & Company Karl Burns - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Greetings and welcome to the DURECT Corporation Fourth Quarter and Full-Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-03-26 22:04:13 |
Czytaj oryginał (ang.) |
| Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates |
Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2025-03-26 20:20:24 |
Czytaj oryginał (ang.) |
| DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif. |
prnewswire.com |
2025-03-26 18:05:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update |
CUPERTINO, Calif. , March 19, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. |
prnewswire.com |
2025-03-19 18:30:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference |
CUPERTINO, Calif. , Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. |
prnewswire.com |
2025-02-04 09:30:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence |
The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial CUPERTINO, Calif. , Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. |
prnewswire.com |
2025-01-28 12:09:00 |
Czytaj oryginał (ang.) |
| Durect (DRRX) Upgraded to Strong Buy: Here's Why |
Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-01-16 15:00:31 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 9th |
AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024. |
zacks.com |
2025-01-09 09:59:29 |
Czytaj oryginał (ang.) |
| Durect (DRRX) Upgraded to Buy: Here's What You Should Know |
Durect (DRRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-11 15:01:22 |
Czytaj oryginał (ang.) |
| DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million |
CUPERTINO, Calif. , Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P. |
prnewswire.com |
2024-11-25 08:00:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript |
DURECT Corporation (NASDAQ:DRRX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jim Brown - Co-Founder, Chief Executive Officer, President, Director Tim Papp - Chief Financial Officer WeiQi Lin - Executive Vice President of Research and Development, Principal Scientist Conference Call Participants Thomas Yip - H.C. Wainwright Karl Burns - Northland Capital Markets Operator Greetings! |
seekingalpha.com |
2024-11-14 00:17:53 |
Czytaj oryginał (ang.) |
| Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates |
Durect (DRRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.40 per share a year ago. |
zacks.com |
2024-11-13 20:11:09 |
Czytaj oryginał (ang.) |
| DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update |
- Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation - Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif. |
prnewswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update |
CUPERTINO, Calif. , Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024. |
prnewswire.com |
2024-11-06 18:45:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 |
CUPERTINO, Calif. , Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the American Association for the Study of Liver Diseases (AASLD), to be held November 15-19, 2024 in San Diego, California. |
prnewswire.com |
2024-10-17 12:30:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis |
- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design - Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of larsucosterol reduced 90-day mortality in U.S. patients by 57% and 58%, respectively, compared with placebo CUPERTINO, Calif. , Sept. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today provided details on the design of its upcoming registrational Phase 3 trial which will evaluate larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH). |
prnewswire.com |
2024-09-25 12:00:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference |
CUPERTINO, Calif. , Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C. |
prnewswire.com |
2024-09-04 20:30:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript |
DURECT Corporation (NASDAQ:DRRX ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Tim Papp - CFO & Secretary Jim Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer Ed Arce - H.C. Wainwright Carl Byrnes - Northland Capital Markets Operator Ladies and gentlemen, welcome to the DURECT Corporation Second Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-14 00:42:05 |
Czytaj oryginał (ang.) |
| Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates |
Durect (DRRX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago. |
zacks.com |
2024-08-13 22:15:23 |
Czytaj oryginał (ang.) |
| DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update |
- FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis - Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design - Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 - Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif. |
prnewswire.com |
2024-08-13 20:01:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update |
CUPERTINO, Calif. , Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August 13, 2024. |
prnewswire.com |
2024-08-07 20:30:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging DURECT (DRRX) This Year? |
Here is how Durect (DRRX) and Elevance Health (ELV) have performed compared to their sector so far this year. |
zacks.com |
2024-06-19 14:45:56 |
Czytaj oryginał (ang.) |
| DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis |
DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May 21, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH). |
prnewswire.com |
2024-05-21 12:00:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript |
DURECT Corporation (NASDAQ:DRRX ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Timothy M. Papp - CFO James E. |
seekingalpha.com |
2024-05-14 01:54:10 |
Czytaj oryginał (ang.) |
| Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates |
Durect (DRRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.52 per share a year ago. |
zacks.com |
2024-05-13 22:21:04 |
Czytaj oryginał (ang.) |
| DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update |
- FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif. |
prnewswire.com |
2024-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update |
CUPERTINO, Calif. , May 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on Monday, May 13, 2024. |
prnewswire.com |
2024-05-07 20:30:00 |
Czytaj oryginał (ang.) |
| DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis |
CUPERTINO, Calif. , April 30, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024 to take place June 5-8, 2024 in Milan, Italy. |
prnewswire.com |
2024-04-30 11:00:00 |
Czytaj oryginał (ang.) |